Science Current Events | Science News |

ESMO publishes updated guidelines on cancer care

July 09, 2010

Enhanced and revised documents provide vital, evidence-based information for treating cancer

The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

The ESMO Clinical Practice Guidelines (CPG) offer vital, evidence-based information including the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up.

Formerly known as the ESMO Clinical Recommendations, the ESMO Clinical Practice Guidelines are intended to provide users with a set of requirements for the highest standard of care for cancer patients.

"The Clinical Practice Guidelines are central to ESMO's mission, which is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice," said ESMO President Prof David Kerr.

A growing number of the new guidelines have been developed using large, multidisciplinary writing groups, ensuring optimal input from the oncology profession and a better geographic representation.

"ESMO is constantly striving to improve the care of cancer patients worldwide," said Prof Kerr. "By developing these new guidelines with the assistance of a wide range of clinicians we can help share the joint expertise of the world's best doctors from many disciplines."

The ESMO Clinical Practice Guidelines include guidelines for breast cancer, colorectal cancer and non-small-cell lung cancer that have been expanded to include more treatment details and further discussion of the importance of multidisciplinary plans for particular patient settings.

Lung cancer is now dealt with in two distinct guidelines, one covering early and locally-advanced cancer, while the other focuses on metastatic disease.

One new guideline is focused specifically on cardiotoxicity, a potential side-effect of some chemotherapeutic agents.

Four further guidelines have been rewritten, drawing on the knowledge of the global oncology community. These include guidelines on soft tissue sarcoma and bone sarcoma, and a guideline on the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

The guideline on the prevention of chemotherapy- and radiotherapy-induced nausea was developed as the result of the 3rd Perugia Consensus Conference organized by the Multinational Association of Supportive Care in Cancer (MASCC) and ESMO.

"ESMO is striving to further increase the value of its guidelines by introducing a more multidisciplinary approach in their development, not only through the use of physical meetings but also through the ESMO Professional Networking Community," said Prof Kerr.

Other guidelines have also been reviewed:

* Pancreatic cancer: including more detail relating to treatment planning in all stages of the disease.

* epatacellular cancer: including an expanded section in surgical and medical treatment, especially targeted therapy.

* Multiple myeloma: revised according to new drug indications.

* Gastrointestinal stromal tumors (GIST): revised with more treatment-orientated details.

* Cancer, fertility and pregnancy: including more information on treatment, especially surgery and highlighting problems of breast, cervical and myeloma cancer in pregnancy as well as further details about delivery of chemotherapy, hormonal and targeted therapy, radiotherapy and supportive agents in pregnant women with cancer.

* Endometrial cancer: including a new section of histology and further guidance on treatment options in these settings.

* Management of febrile neutropenia: including more detail on treatment assessments and how to manage patients.

The new guidelines published in June represent the first stage of a process that will include guidelines for more than 55 different clinical situations, covering almost all tumor types as well as various other topics, including the therapeutic use of growth factors.

European Society for Medical Oncology

Related Clinical Practice Current Events and Clinical Practice News Articles

Endocrine experts call for more research into leading cause of infertility
More research is needed to better understand polycystic ovary syndrome - one of the leading causes of infertility, according to the Scientific Statement issued by the Endocrine Society.

New ASTRO template helps radiation oncologists guide cancer survivors through ongoing care
A new template published by the American Society for Radiation Oncology (ASTRO) standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy (RT).

Subsolid lung nodules pose greater cancer risk to women than men
Women with a certain type of lung nodule visible on lung cancer screening CT exams face a higher risk of lung cancer than men with similar nodules, according to a new study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

Biomarkers in medicine explores the translation of biomarkers into regulatory science
Biomarkers in Medicine, a leading MEDLINE-indexed journal, has published a special focus issue exploring the increasingly important role of biomarkers in both drug development and regulatory decision making. Biomarkers in Medicine is published by Future Science Group.

Early use of antibiotic for recurrent, severe lower respiratory illness in children
Among young children with histories of recurrent severe lower respiratory tract illness (LRTI), the use of azithromycin early during an apparent RTI compared with placebo significantly reduced the risk of experiencing progression to severe LRTI.

Researchers devise new diabetes diagnostic tool
Researchers at University of Exeter have developed a new test to help diagnoses diabetes, which they say will lead to more effective diagnosis and patient care.

Feeding at-risk infants gluten increases risk of developing celiac disease
Intake of gluten up until two years of age increases risk of celiac disease at least two-fold in children with genetic risk factors for this disease, according a study published in Clinical Gastroenterology and Hepatology the official clinical practice journal of the American Gastroenterological Association.

New treatment option may be on the horizon for polymyalgia rheumatica
A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

Steps forward in the hunt for easily measurable biomarkers of autism
Future Science Group (FSG) today announced the publication of a new article in Future Science OA, reporting data demonstrating the possibility of measuring 10 biomarkers relevant to autism spectrum disorder in adult saliva.

An effective integrated reproductive strategy for hearing loss by researches from China
Hearing impairment is a major public health problem in the world, affecting over 5% of the world's population - 360 million people, including 328 million adults and 32 million children.
More Clinical Practice Current Events and Clinical Practice News Articles

© 2015